Literature DB >> 10568179

Detection of circulating tumor cells by reverse transcriptase-polymerase chain reaction in patients with resectable non-small-cell lung cancer.

Y Kurusu1, J Yamashita, M Ogawa.   

Abstract

OBJECTIVE: We tested whether circulating tumor cells can be detected in the peripheral blood of patients with resectable non-small-cell lung cancer (NSCLC) by reverse transcriptase-polymerase chain reaction (RT-PCR) of carcinoembryonic antigen (CEA) mRNA.
METHODS: We assayed for CEA mRNA by RT-PCR in the peripheral blood, taken at the time of diagnosis before surgical intervention and again 2 to 3 weeks postoperatively, from 103 patients with NSCLC who underwent curative lobectomy. Blood samples taken from 15 patients with interstitial pulmonary fibrosis who underwent an open-lung biopsy and from 32 healthy subjects served as controls.
RESULTS: No control samples were positive for CEA by RT-PCR. Sixty-two (60%) of the preoperative blood samples from the 103 patients with NSCLC were positive. Of these 62 samples, 27 (44%) remained positive even after surgical intervention, whereas the remaining 35 samples (56%) became negative. The incidence of positive CEA mRNA correlated highly with pathologic TNM stage of disease in both the preoperative and postoperative blood samples.
CONCLUSIONS: Many patients with resectable NSCLC have detectable levels of circulating cells expressing carcinoembryonic antigen even after surgical intervention. Such patients may have a higher rate of relapse.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10568179

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  17 in total

1.  Observation of circulating tumour cells in patients with non-small cell lung cancer by real-time fluorescent quantitative reverse transcriptase-polymerase chain reaction in peroperative period.

Authors:  Ming Jian Ge; De Shi; Qing Chen Wu; Mei Wang; Liang Bin Li
Journal:  J Cancer Res Clin Oncol       Date:  2005-12-01       Impact factor: 4.553

2.  Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance).

Authors:  Linda W Martin; Jonathan D'Cunha; Xiaofei Wang; Debra Herzan; Lin Gu; Naif Abraham; Todd L Demmy; Frank C Detterbeck; Shawn S Groth; David H Harpole; Mark J Krasna; Kemp Kernstine; Leslie J Kohman; G Alexander Patterson; David J Sugarbaker; Robin T Vollmer; Michael A Maddaus; Robert A Kratzke
Journal:  J Clin Oncol       Date:  2016-02-29       Impact factor: 44.544

3.  Circulating tumor cells are associated with poor outcomes in early-stage hepatocellular carcinoma: a prospective study.

Authors:  Yeonjung Ha; Tae Hun Kim; Jae Eul Shim; Sunghyun Yoon; Mi Jung Jun; Young-Ho Cho; Han Chu Lee
Journal:  Hepatol Int       Date:  2019-11-05       Impact factor: 6.047

4.  Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration.

Authors:  Jay M Lee; Mi-Heon Lee; Edward Garon; Jonathan W Goldman; Ramin Salehi-Rad; Felicita E Baratelli; Dörthe Schaue; Gerald Wang; Fran Rosen; Jane Yanagawa; Tonya C Walser; Ying Lin; Stacy J Park; Sharon Adams; Francesco M Marincola; Paul C Tumeh; Fereidoun Abtin; Robert Suh; Karen L Reckamp; Gina Lee; William D Wallace; Sarah Lee; Gang Zeng; David A Elashoff; Sherven Sharma; Steven M Dubinett
Journal:  Clin Cancer Res       Date:  2017-05-03       Impact factor: 12.531

Review 5.  Circulating tumor cells in lung cancer: detection methods and clinical applications.

Authors:  Na Yu; Jia Zhou; Fang Cui; Xiaokui Tang
Journal:  Lung       Date:  2015-02-19       Impact factor: 2.584

6.  Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood [corrected].

Authors:  Michael Mitas; Loretta Hoover; Gerard Silvestri; Carolyn Reed; Mark Green; Andrew T Turrisi; Carol Sherman; Kaidi Mikhitarian; David J Cole; Mark I Block; William E Gillanders
Journal:  J Mol Diagn       Date:  2003-11       Impact factor: 5.568

7.  Circulating tumor cells in peripheral blood caused by surgical manipulation of non-small-cell lung cancer: pilot study using an immunocytology method.

Authors:  Noriyoshi Sawabata; Meinoshin Okumura; Tomoki Utsumi; Masayoshi Inoue; Hiroyuki Shiono; Masahito Minami; Toshirou Nishida; Yoshiki Sawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2007-05

8.  Highly efficient circulating tumor cell isolation from whole blood and label-free enumeration using polymer-based microfluidics with an integrated conductivity sensor.

Authors:  André A Adams; Paul I Okagbare; Juan Feng; Matuesz L Hupert; Don Patterson; Jost Göttert; Robin L McCarley; Dimitris Nikitopoulos; Michael C Murphy; Steven A Soper
Journal:  J Am Chem Soc       Date:  2008-06-17       Impact factor: 15.419

9.  Transcription expression and clinical significance of dishevelled-3 mRNA and δ-catenin mRNA in pleural effusions from patients with lung cancer.

Authors:  Xiao-Yan Li; Shu-Li Liu; Na Cha; Yu-Jie Zhao; Shao-Cheng Wang; Wei-Nan Li; En-Hua Wang; Guang-Ping Wu
Journal:  Clin Dev Immunol       Date:  2012-02-23

10.  Revisiting perioperative chemotherapy: the critical importance of targeting residual cancer prior to wound healing.

Authors:  William W Harless
Journal:  BMC Cancer       Date:  2009-04-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.